Contact – +1-276-477-5910
 Email – [email protected]

Home >>

Healthcare and Social Assistance

>>

Business Opportunities and Investment Strategies for Global Regenerative Medicine Market


Business Opportunities and Investment Strategies for Global Regenerative Medicine Market 2023-2033

Report code: SDMRGM1703189 | Industry: Healthcare and Social Assistance | Published On: 2024-06-07


Opportunity and Strategy Analysis
This report focuses on identifying opportunities and strategies for investing in the global regenerative medicine market within the forecast period. It provides a complete analysis of the global market both quantitatively and qualitatively. The quantitative analysis includes market size and revenue data of the total demand, sub-markets, and regional/national levels throughout 2023-2033. Qualitative analysis depicts a full picture of market dynamics and trends including drivers, restraints and challenges, emerging products/market trends, and Porter’s Fiver Forces analysis.

Based on the market data and analysis, the report highlights Increasingly Attractive Segments (IAS) and business opportunities in each segmentation. Moreover, a systematic evaluation of Internal Risks (factors arising within the industry development) and External Risks (factors arising from the surrounding environments) is provided for the regenerative medicine industry and market. All the identified risk factors are measured quantitatively according to GMD’s novel numeric system, i.e. each risk is evaluated with GMD Risk Index Number (GMD RIN) and GMD Risk Intensity Level (GMD RIL). This in-depth risk assessment offers a comprehensive understanding of the current risk factors and their developing trends. Furthermore, this report concludes risk management strategies and Critical Success Factors (CSFs) to help companies make intelligence-based business decisions in the global regenerative medicine industry.

Market Coverage & Overview
The report is based on studies for 2021-2023 and provides a forecast from 2024 till 2033 with 2023 as the base year. Considering impact of COVID-19 and regional conflicts such as Russia-Ukraine war, the trend and outlook of global market is forecast in optimistic, balanced, and conservative scenarios. In the balanced view, the global regenerative medicine market is expected to reach $117.43 billion by 2033, growing by 17.9% annually over the coming years.

Segmentation Analysis
Highlighted with 87 tables and 93 figures, this 186-page report represents a 360-degree view on the global market with extensively detailed segmentations by Therapy, Material, Application, End User, and Region/Country as shown below. Annual revenue 2023-2033 for each segment is included in the report.

By Therapy
• Tissue-based Therapy
• Gene-based Therapy
• Cell-based Therapy
• Small Molecule & Biologic

By Material
• Synthetic Material
• Biologically Derived Material
• Genetically Engineered Material
• Other Materials

By Application
• Oncology
• Musculoskeletal
• Dermatology & Wound Care
• Immunology and Inflammation
• Cardiovascular Diseases
• Ophthalmology
• Other Applications

By End User
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Other End Users

By Region
• North America (U.S., Canada, and Mexico)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (UAE, Saudi Arabia, South Africa, and Rest of MEA)
The breakdown of all regional markets by country and the breakdown of each national market by Therapy, Application, and End User over the forecast years are also included.

Key Companies
The report also covers the current competitive scenario and profiles key vendors including market leaders and important emerging players. A selection of companies profiled in this report includes:
• AbbVie Inc.
• Amgen, Inc.
• AstraZeneca plc
• Baxter International Inc.
• Bayer AG
• Becton Dickinson and Company
• Bristol-Myers Squibb Company
• Cook Biotech Inc.
• F. Hoffmann La Roche Ltd.
• Gilead Sciences, Inc.
• GlaxoSmithKline (GSK)
• Integra Lifesciences Corp.
• Medtronic PLC
• Merck KgaA
• Mimedx Group, Inc.
• Novartis AG
• Organogenesis Inc.
• Smith and Nephew plc
• Takeda Pharmaceutical Company Limited
• Thermo Fisher Scientific Inc.
• Vericel Corporation

1  Introduction 9
1.1  Industry  Definition  and  Research  Scope 9
1.1.1  Industry  Definition 9
1.1.2  Research  Scope 10
1.2  Research  Methodology 13
1.2.1  Overview  of  Market  Research  Methodology 13
1.2.2  Market  Assumption 14
1.2.3  Secondary  Data 14
1.2.4  Primary  Data 14
1.2.5  Data  Filtration  and  Model  Design 15
1.2.6  Market  Size/Share  Estimation 16
1.2.7  Research  Limitations 17
1.3  Executive  Summary 18
2  Market  Overview  and  Dynamics 21
2.1  Market  Size  and  Forecast 21
2.1.1  Impact  of  COVID-19  on  World  Economy 22
2.1.2  Impact  of  COVID-19  on  the  Market 26
2.1.3  Impact  of  Russia-Ukraine  Conflict 28
2.1.4  Impact  of  Israel-Palestine  War 30
2.2  Major  Growth  Drivers 31
2.3  Market  Restraints  and  Challenges 37
2.4  Emerging  Opportunities  and  Market  Trends 40
2.5  Porter’s  Fiver  Forces  Analysis 43
3  Segmentation  of  Global  Market  by  Therapy 47
3.1  Market  Overview  by  Therapy 47
3.2  Tissue-based  Therapy 50
3.3  Gene-based  Therapy 51
3.4  Cell-based  Therapy 52
3.5  Small  Molecule  &  Biologic 53
4  Segmentation  of  Global  Market  by  Material 54
4.1  Market  Overview  by  Material 54
4.2  Synthetic  Material 57
4.3  Biologically  Derived  Material 58
4.4  Genetically  Engineered  Material 59
4.5  Other  Materials 60
5  Segmentation  of  Global  Market  by  Application 61
5.1  Market  Overview  by  Application 61
5.2  Oncology 64
5.3  Musculoskeletal 65
5.4  Dermatology  &  Wound  Care 66
5.5  Immunology  and  Inflammation 67
5.6  Cardiovascular  Diseases 68
5.7  Ophthalmology 69
5.8  Other  Applications 70
6  Segmentation  of  Global  Market  by  End  User 71
6.1  Market  Overview  by  End  User 71
6.2  Hospitals  &  Clinics 74
6.3  Ambulatory  Surgical  Centers 75
6.4  Other  End  Users 76
7  Segmentation  of  Global  Market  by  Region 77
7.1  Geographic  Market  Overview  2023-2033 77
7.2  North  America  Market  2023-2033  by  Country 82
7.2.1  Overview  of  North  America  Market 82
7.2.2  U.S. 86
7.2.3  Canada 89
7.2.4  Mexico 91
7.3  European  Market  2023-2033  by  Country 93
7.3.1  Overview  of  European  Market 93
7.3.2  Germany 97
7.3.3  U.K. 99
7.3.4  France 101
7.3.5  Spain 103
7.3.6  Italy 105
7.3.7  Russia 107
7.3.8  Rest  of  European  Market 109
7.4  Asia-Pacific  Market  2023-2033  by  Country 111
7.4.1  Overview  of  Asia-Pacific  Market 111
7.4.2  Japan 115
7.4.3  China 118
7.4.4  Australia 120
7.4.5  India 122
7.4.6  South  Korea 124
7.4.7  Rest  of  APAC  Region 126
7.5  South  America  Market  2023-2033  by  Country 128
7.5.1  Argentina 132
7.5.2  Brazil 134
7.5.3  Chile 136
7.5.4  Rest  of  South  America  Market 138
7.6  MEA  Market  2023-2033  by  Country 139
7.6.1  UAE 143
7.6.2  Saudi  Arabia 145
7.6.3  South  Africa 147
7.6.4  Other  National  Markets 149
8  Competitive  Landscape 150
8.1  Overview  of  Key  Vendors 150
8.2  New  Product  Launch,  Partnership,  Investment,  and  M&A 153
8.3  Company  Profiles 154
AbbVie  Inc. 154
Amgen,  Inc. 156
AstraZeneca  plc 157
Baxter  International  Inc. 158
Bayer  AG 159
Becton  Dickinson  and  Company 160
Bristol-Myers  Squibb  Company 161
Cook  Biotech  Inc. 162
F.  Hoffmann  La  Roche  Ltd. 163
Gilead  Sciences,  Inc. 164
GlaxoSmithKline  (GSK) 165
Integra  Lifesciences  Corp. 166
Medtronic  PLC 167
Merck  KgaA 168
Mimedx  Group,  Inc. 169
Novartis  AG 170
Organogenesis  Inc. 171
Smith  and  Nephew  plc 172
Takeda  Pharmaceutical  Company  Limited 173
Thermo  Fisher  Scientific  Inc. 174
Vericel  Corporation 175
9  Investing  in  Regenerative  Medicine  Industry:  Risk  Assessment  and  Management 176
9.1  Risk  Evaluation  of  Global  Market 176
9.2  Critical  Success  Factors  (CSFs) 183
RELATED  REPORTS 186
To know more, kindly contact [email protected]
 Feel free to contact us

 
Choose License Type
Select User Type


Report code




x

Use Code

SDMR20

Purchase any report

AVAIL FLAT DISCOUNT